EQS-News: MEDICLIN on track: business development in line with expectations
|
EQS-News: MEDICLIN AG
/ Key word(s): 9 Month figures/Miscellaneous
Offenburg, 4 November 2025
MEDICLIN on track: business development in line with expectations
Offenburg, 4 November 2025: MEDICLIN Aktiengesellschaft (ticker: MED; WKN 659 510) generated consolidated group sales of EUR 586.9 million in the first nine months of 2025. This corresponds to an increase of EUR 28.7 million or 5.1% compared with the same period last year. Group operating result amounted to EUR 48.9 million (9M 2024: EUR 34.5 million). Overall capacity utilisation within the Group remained stable at 86.8% (9M 2024: 86.0%).
Developments in the segments In the post-acute segment, sales increased by 9.3% to EUR 394.6 million (9M 2024: EUR 361.2 million). Segment operating result rose by EUR 9.6 million to EUR 47.6 million (9M 2024: EUR 38.0 million). The cost of materials ratio fell by 0.9 percentage points to 19.5% (9M 2024: 20.4%). Total cost of materials amounted to EUR 77.0 million, representing an increase of 4.4% compared with the same period of the previous year (9M 2024: EUR 73.8 million). Personnel expenses increased by EUR 17.6 million or 9.4% to EUR 205.0 million, mainly due to salary increases and a higher number of employees. The personnel expense ratio remained unchanged at 51.9%. Developments in the acute segment were significantly influenced by the sale of the former MEDICLIN Herzzentrum Coswig. Segment sales decreased by EUR 5.7 million or 3.2%. The cost of materials fell by 4.8% to EUR 47.6 million (9M 2024: EUR 50.0 million). The cost of materials ratio declined slightly to 28.0% (9M 2024: 28.5%). Personnel expenses amounted to EUR 101.0 million, down 4.8% on the previous year (9M 2024: EUR 106.1 million). At 59.4%, the personnel expense ratio was one percentage point below the previous year's level (9M 2024: 60.4%). The segment’s operating result improved by a total of EUR 4.5 million or 117.2% to EUR 0.7 million (9M 2024: EUR –3.8 million). Sales in the nursing care segment amounted to EUR 18.6 million in the first nine months of 2025 (9M 2024: EUR 17.5 million), while the segment operating result was EUR –0.4 million, down EUR 0.5 million on the same period of the previous year (9M 2024: EUR 0.1 million). Sales in the service segment increased by EUR 3.3 million to EUR 74.8 million (9M 2024: EUR 71.5 million). At EUR 1.0 million, the segment operating result was EUR 0.8 million higher than in the same period of the previous year (9M 2024: EUR 0.2 million). Outlook and current events The Management Board confirms its guidance for the 2025 financial year, with consolidated group sales to grow by between 2.0% and 5.0% and consolidated group EBIT between EUR 53.0 million and EUR 64.0 million. “In view of the current conditions and typical seasonal effects in the fourth quarter, we continue to assess business development as solid. With the current quarterly results, we are demonstrating that we will achieve our original annual guidance and successfully conclude the current financial year,” comments Tino Fritz, CFO of MEDICLIN. The interim report as of 30 September 2025 is available in German and English at www.mediclin.de as of today. For further information: MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Investor Relations Ender Gülcan Tel.: +49781/488-326 ender.guelcan@mediclin.de www.mediclin.de About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN includes 31 clinics, six care facilities and nine medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs. MEDICLIN ─ a company of the Asklepios Group
04.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | MEDICLIN AG |
| Okenstraße 27 | |
| 77652 Offenburg | |
| Germany | |
| Phone: | +49 (0)781 488-326 |
| Fax: | +49 (0)781 488-184 |
| E-mail: | ender.guelcan@mediclin.de |
| Internet: | www.mediclin.de |
| ISIN: | DE0006595101 |
| WKN: | 659510 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2223588 |
| End of News | EQS News Service |
|
|
2223588 04.11.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 673,09 | 659,86 | 673,14 | 704,70 | 730,07 | 748,75 | 778,00 | |
| EBITDA1,2 | 93,58 | 77,50 | 85,22 | 90,92 | 98,73 | 103,77 | 115,00 | |
| EBITDA-Margin3 | 13,90 | 11,75 | 12,66 | 12,90 | 13,52 | 13,86 | 14,78 | |
| EBIT1,4 | 22,41 | 0,15 | 11,56 | 19,52 | 12,72 | 53,49 | 63,00 | |
| EBIT-Margin5 | 3,33 | 0,02 | 1,72 | 2,77 | 1,74 | 7,14 | 8,10 | |
| Net Profit (Loss)1 | 9,68 | -0,04 | 1,49 | 9,72 | -10,72 | 24,91 | 35,00 | |
| Net-Margin6 | 1,44 | -0,01 | 0,22 | 1,38 | -1,47 | 3,33 | 4,50 | |
| Cashflow1,7 | 69,59 | 118,69 | 81,97 | 34,64 | 78,00 | 50,57 | 74,00 | |
| Earnings per share8 | 0,20 | -0,19 | 0,03 | 0,20 | -0,23 | 0,52 | 0,74 | |
| Dividend per share8 | 0,05 | 0,00 | 0,00 | 0,00 | 0,00 | 0,04 | 0,04 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Mediclin | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 659510 | DE0006595101 | AG | 179,55 Mio € | 06.12.2000 | Kaufen | 8FW9FWGV+63 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 5,82 | 17,70 | 0,33 | 17,10 | 0,73 | 2,23 | 0,24 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,04 | 0,04 | 1,06% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 28.06.2026 | 04.05.2026 | 30.07.2026 | 04.11.2025 | 27.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +12,80% | +22,77% | +56,20% | +52,42% | -65,64% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.